EOLS (Evolus) ROCE % : -32.77% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Evolus ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Evolus's annualized ROCE % for the quarter that ended in Sep. 2024 was -32.77%.

Evolus ROCE % Historical Data

The historical data trend for Evolus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus ROCE % Chart

Evolus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-50.77

-124.53

-39.69

-39.37

-35.03

Evolus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-42.46	-23.53	-20.89	-14.73	-32.77

Evolus ROCE % Calculation

Evolus's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-47.677	/	( ( (177.983 - 46.509)	+	(188.998 - 48.291) )	/ 2 )
	=	-47.677	/	( (131.474	+	140.707)	/ 2 )
	=	-47.677	/	136.0905
	=	-35.03 %

Evolus's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-57.088	/	( ( (233.772 - 54.118)	+	(229.608 - 60.815) )	/ 2 )
	=	-57.088	/	( ( 179.654	+	168.793 )	/ 2 )
	=	-57.088	/	174.2235
	=	-32.77 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Evolus (NAS:EOLS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Evolus ROCE % Related Terms

Thank you for viewing the detailed overview of Evolus's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0K16:UK EVL:Germany

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Executives

Sandra Beaver	officer: Chief Financial Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Tomoko Yamagishi-dressler	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
David Moatazedi	director, officer: See Remarks	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Vikram Malik	director	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Rui Avelar	officer: See Remarks	1618 STATION STREET, VANCOUVER A1 V6A 1B6
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949
Medytox Inc.	10 percent owner	78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Alphaeon 1 Llc	10 percent owner	4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman	director	8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank	director	C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail	officer: See Remarks	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Crystal Muilenburg	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart	director	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660